Japan Tobacco Inc (JAPAF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com
06 Nov 2024
  • Revenue: Increased both at constant FX and on a reported basis.
  • Adjusted Operating Profit (AOP): Increased 2.6% year on year at constant FX.
  • Operating Profit: Increased 0.8% year on year.
  • Free Cash Flow: Decreased by JPY159.8 billion to JPY260.5 billion.
  • Tobacco Business Volume: Total volume grew by 2.2% year on year.
  • Combustibles Volume: Increased by 1.8% year on year.
  • RRP Volume: Increased by 22.8% year on year.
  • Ploom Volume: Increased by 40% year on year to 5.9 billion units.
  • RRP-Related Revenue: Increased by approximately 22% year on year.
  • Vector Acquisition: Total value approximately USD2.4 billion, increasing US market share from 2.4% to 8.2%.
  • Pharmaceutical Business Revenue: Decreased by JPY2.8 billion.
  • Processed Food Business Revenue: Increased by JPY2 billion.
  • Dividend Payout Ratio: Approximately 74%, with annual dividend per share forecast at JPY194.
  • Warning! GuruFocus has detected 4 Warning Sign with BLX.

Release Date: October 31, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Japan Tobacco Inc (JAPAF) reported an increase in revenue and adjusted operating profit (AOP) both at constant FX and on a reported basis, driven primarily by the tobacco business.
  • The company's tobacco business saw a 2.2% year-on-year increase in total volume, with significant growth in the Reduced-Risk Products (RRP) segment, particularly Ploom, which increased by 22.8%.
  • The acquisition of Vector Group is expected to significantly increase Japan Tobacco Inc (JAPAF)'s market share in the US from 2.4% to 8.2%, enhancing its competitiveness in the US market.
  • The processed food business contributed positively to the company's performance, with revenue and profit increasing year on year due to price revisions and steady sales growth.
  • Japan Tobacco Inc (JAPAF) revised its full-year forecast upward for consolidated revenue and AOP, reflecting strong business momentum and the contribution from the Vector acquisition.

Negative Points

  • The financial contribution of volume to AOP was negative due to a higher volume contribution from lower-margin markets, impacting overall profitability.
  • Free cash flow decreased by JPY159.8 billion to JPY260.5 billion due to a temporary deterioration in working capital, including the impact of tobacco tax payment schedules.
  • The impact of foreign exchange was unfavorable to AOP, with the depreciation of emerging market currencies and appreciation of cost-related currencies offsetting the positive impact of a weaker yen.
  • The pharmaceutical business saw a decrease in revenue and AOP due to the absence of one-time compensation gains and lower overseas royalty income.
  • The Canadian litigation poses a potential financial risk, with the possibility of a CAD32.5 billion settlement impacting future dividend payouts.

Q & A Highlights

Q: What is the potential margin upside from the Vector acquisition in the US market, and what are the drivers? A: Nobuya Kato, Deputy CEO, explained that while specific margin contributions cannot be disclosed, the US market is high in profitability, and the acquisition is expected to improve the ROI of the global tobacco business. Despite industry volume declines, pricing strategies should secure margins. The acquisition also provides stable profit contributions in hard currency, which is beneficial for the company's financial stability.

Q: Regarding your M&A strategy and use of cash, will you prioritize business investments over share buybacks? A: Hiromasa Furukawa, CFO, stated that the company aims to maintain a robust balance sheet to pursue attractive investment opportunities. M&A remains a growth strategy, focusing on HTS and combustibles. While dividends are central to shareholder returns, share buybacks will be considered based on financial conditions and business environment.

Q: Will the acquisition of Vector accelerate investment into RRP? A: Nobuya Kato clarified that while the acquisition increases cash and profit, it does not directly lead to additional RRP investment. The company has already increased RRP investment plans and will use the acquisition to secure resources for potential future investments.

Q: How will the Canadian litigation impact dividends, and what is the timeline for resolution? A: Hiromasa Furukawa mentioned that while the settlement amount is not finalized, any potential losses could lead to dividend adjustments. The company aims to minimize dividend impact, but specifics depend on the settlement's outcome and timing, which are currently uncertain.

Q: With the upward revision of AOP and the impact of Vector, what factors contributed to this revision? A: Nobuya Kato noted that the Vector acquisition has contributed to AOP since its consolidation. Organic business growth, moderate supply chain costs, and top-line improvements also played a role in the upward revision.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10